Other studies have shown that long-term treatment of ovarian cancer cells with the anti-Her2-antibody trastuzumab potentiated the responsiveness to gefitinib and cetuximab significantly, although the cells were functionally resistant to trastuzumab [36]. Here, ERBB2 is linked to ovarian carcinoma.